Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Leaders Confront Another Daunting Challenge: Meeting COVID-19 Demand

Executive Summary

Pharma leaders at the CNBC Healthy Returns virtual conference said they are optimistic industry will deliver a SARS-COV-2 vaccine, but ramping up the supply will require time and collaboration.

You may also be interested in...

Remdesivir Distribution Begins With More Questions Than Answers

Ethicists decry the government's opaque approach, highlighting the potential risks of a fast US FDA emergency authorization if supply isn't able to support demand following regulatory clearance. AmerisourceBergen is distributing the drug for the government, but within the Administration, no agency appears to want to take public responsibility for the decisions about where the doses of the COVID-19 treatment are sent.

Moderna’s COVID-19 Vaccine To Move Faster Into Phase III

mRNA company confident as it heads towards Phase II trials, but says efficacy and approval will not be a ‘binary event’.

Regeneron Maintains Its Momentum During Pandemic

The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts